varenicline pfizer
pfizer new zealand limited - varenicline tartrate 1.71mg equivalent to 1 mg varenicline; ; - film coated tablet - 1 mg - active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation
varenicline pfizer 0.5 mg and 1 mg tablets
pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline; ; ; varenicline tartrate 1.71mg equivalent to 1 mg varenicline - combination - 0.5 mg and 1 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation
synarel- nafarelin acetate spray, metered
pfizer laboratories div pfizer inc - nafarelin acetate (unii: 8enz0qjw4h) (nafarelin - unii:1x0094v6jv) - nafarelin 2 mg in 1 ml - (for endometriosis, see reverse side ) synarel is indicated for treatment of central precocious puberty (cpp) (gonadotropin-dependent precocious puberty) in children of both sexes. the diagnosis of central precocious puberty (cpp) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. the diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal lh response to stimulation by native gnrh. pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. magnetic resonance imaging or ct-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular
pfizer (australia) gentamicin 80 mg/2 ml (as sulfate) injection bp ampoule
pfizer australia pty ltd - gentamicin, quantity: 80 mg - injection, solution - excipient ingredients: sulfuric acid; water for injections; sodium hydroxide; disodium edetate - indications as at november 2000; for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibi
pfizer (australia) cytarabine 2g/20ml injection vial
pfizer australia pty ltd - cytarabine, quantity: 2 g - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa212) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.
pfizer (australia) cytarabine 1g/10ml injection vial
pfizer australia pty ltd - cytarabine, quantity: 1 g - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with
pfizer (australia) cytarabine 100mg/5ml injection vial
pfizer australia pty ltd - cytarabine, quantity: 100 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with
daurismo- glasdegib tablet, film coated
pfizer laboratories div pfizer inc - glasdegib (unii: k673dmo5h9) (glasdegib - unii:k673dmo5h9) - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. none. risk summary based on its mechanism of action and findings in animal embryo-fetal developmental toxicity studies, daurismo can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no clinical data on the use of daurismo in pregnant women to inform of a drug-associated risk of major birth defects and miscarriage. daurismo is not recommended for use during pregnancy. conduct pregnancy testing in female patients of reproductive potential prior to initiating treatment with daurismo. report pregnancy exposures to pfizer at 1-800-438-1985. in animal embryo-fetal developmental toxicity studies, repeat-dose oral administration of daurismo during organogenesis at maternal exposures that were less than the human exposu
comirnaty pbs
pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - concentrate for dispersion for injection - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines - comirnaty is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 virus, in individuals 12 years of age and older.
comirnaty tris 30
pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - concentrate for dispersion for injection - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines - comirnaty is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 virus, in individuals 12 years of age and older.